Abstract
Introduction: To date, there is no permanent medical treatment for nasal polyposis and loss of sense of smell. Mepolizumab is an anti-IL-5 monoclonal antibody approved for the treatment of patients with eosinophilic asthma. It has been suggested that it is capable of improving olfactory dysfunction in patients with chronic rhinosinusitis and nasal polyposis.
Case: We present a 35-year-old Emirati male with progressively worsening rhinosinusitis, recurring nasal polyps and total loss of sense of smell. He was treated with oral steroids, normal saline nasal sprays and all available topical steroids without significant or permanent symptom relief. He was commenced on Mepolizumab, and upon receiving the 4th dose, he reported full recovery of his sense of smell.
Conclusion: Mepolizumab appears to be very effective in treating loss of sense of smell. Further studies should be conducted to assess the efficacy and effectiveness of Mepolizumab in patients with chronic rhinosinusitis, nasal polyposis and anosmia.
Keywords: Mepolizumab, Nasal polyps, Olfaction disorders, Sinusitis, Paranasal sinus diseases, Rhinosinusitis.
New Emirates Medical Journal
Title:Recovery of Sense of Smell by Mepolizumab in a Patient with Chronic Rhinosinusitis and Nasal Polyposis
Volume: 1
Author(s): Mohamed Abuzakouk*, Omar Ghorab, Safieeldin Ghazala and Anastasios Hantzakos
Affiliation:
- Department of Allergy and Immunology, Cleveland Clinic Abu Dhabi, Abu Dhabi,United Arab Emirates
Keywords: Mepolizumab, Nasal polyps, Olfaction disorders, Sinusitis, Paranasal sinus diseases, Rhinosinusitis.
Abstract:
Introduction: To date, there is no permanent medical treatment for nasal polyposis and loss of sense of smell. Mepolizumab is an anti-IL-5 monoclonal antibody approved for the treatment of patients with eosinophilic asthma. It has been suggested that it is capable of improving olfactory dysfunction in patients with chronic rhinosinusitis and nasal polyposis.
Case: We present a 35-year-old Emirati male with progressively worsening rhinosinusitis, recurring nasal polyps and total loss of sense of smell. He was treated with oral steroids, normal saline nasal sprays and all available topical steroids without significant or permanent symptom relief. He was commenced on Mepolizumab, and upon receiving the 4th dose, he reported full recovery of his sense of smell.
Conclusion: Mepolizumab appears to be very effective in treating loss of sense of smell. Further studies should be conducted to assess the efficacy and effectiveness of Mepolizumab in patients with chronic rhinosinusitis, nasal polyposis and anosmia.
Export Options
About this article
Cite this article as:
Abuzakouk Mohamed *, Ghorab Omar , Ghazala Safieeldin and Hantzakos Anastasios , Recovery of Sense of Smell by Mepolizumab in a Patient with Chronic Rhinosinusitis and Nasal Polyposis, New Emirates Medical Journal 2020; 1 (2) . https://dx.doi.org/10.2174/0250688202002022006
DOI https://dx.doi.org/10.2174/0250688202002022006 |
Print ISSN 0250-6882 |
Publisher Name Bentham Science Publisher |
Online ISSN 0250-6882 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lecithin (Phosphatidylcholine): Healthy Dietary Supplement or Dangerous Toxin?
The Natural Products Journal Mechanisms Involved in Apoptosis Events Contributing to Sepsis-Induced Myocardial Dysfunction
Current Drug Therapy The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design Resveratrol Targets in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Multi-target Activities of Selected Alkaloids and Terpenoids
Mini-Reviews in Organic Chemistry Probiotics as an Adjuvant Therapy in Major Depressive Disorder
Current Neuropharmacology A Novel Combination of ω-3 Fatty Acids and Nano-Curcumin Modulates Interleukin-6 Gene Expression and High Sensitivity C-reactive Protein Serum Levels in Patients with Migraine: A Randomized Clinical Trial Study
CNS & Neurological Disorders - Drug Targets The Effects of Vitamin B in Depression
Current Medicinal Chemistry Pathogenesis of Neointima Formation Following Vascular Injury
Cardiovascular & Hematological Disorders-Drug Targets Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology Synthesis of Hybrids of Dihydropyrimidine and Pyridazinone as potential Anti-Breast Cancer Agents
Mini-Reviews in Medicinal Chemistry Adverse Cutaneous Reactions of Systemic Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Correlation Between ROS Production and InsP3 Released by Granulocytes from Type 1 Diabetic Patients in a cAMP-Dependent Manner
Current Aging Science 1,8-Naphthyridine Derivatives: A Privileged Scaffold for Versatile Biological Activities
Mini-Reviews in Medicinal Chemistry Pathologic Findings of Autoimmune Pancreatitis and IgG4-Related Disease
Current Immunology Reviews (Discontinued) Possible Role of BDNF-Induced Microglial Intracellular Ca<sup>2+</sup> Elevation in the Pathophysiology of Neuropsychiatric Disorders
Mini-Reviews in Medicinal Chemistry Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy
Current Medicinal Chemistry Oxidative Metabolism of Endocannabinoids by COX-2
Current Pharmaceutical Design Elevated Interleukin 37 Expression Associated With Disease Activity in HLA-B27 Associated Anterior Uveitis and Idiopathic Anterior Uveitis
Current Molecular Medicine Brain-Skin Connection: Stress, Inflammation and Skin Aging
Inflammation & Allergy - Drug Targets (Discontinued)